|
Hier ein schöner Artikel, den ich soeben gefunden habe: Endocyte Inc. (ECYT): ECYT develops targeted therapies using small molecule drug conjugates for the treatment of cancer and inflammatory diseases. On Tuesday, Boston-based biotech focused hedge fund RA Capital Management filed SEC form SC 13G indicating that it now holds 2.6 million or 7.3% of outstanding shares, an increase of 2.2 million shares from the 0.4 million shares that it held at the time of its 13-F Q3 filing. We wrote recently about RA Capital’s top biotech new buys and sells in Q3, noting that ECYT was a new purchase in Q3. This is the second biotech-focused institutional investor that has purchased ECYT recently as we noted just last Thursday that CA-based venture capital firm Sanderling Venture Partners that specializes in investing in biotech companies filed SEC Forms 4 indicating that they purchased an additional 440,000 shares for $1.4 million, increasing their ownership to 4.5 million shares. Furthermore, insiders have also been on a buying spree at ECYT recently, as five insiders together reported purchasing 226,000 shares in December. ECYT shares are among December’s strongest movers to the downside (down by two-thirds so far), after the company announced on December 13th the results of supplemental analyses of its phase 2b PRECEDENT trial. The heavy insider and sector-focused institutional buying is particularly notable in this context as it signifies that knowledgeable insiders and institutions through their buying of company shares seem to think that the selling is overdone here, portending that we may be near a bottom. We are very bullish on shares of (ECYT) and we are placing a short term price target of $6.50 cents a share. The chart is getting stronger insiders and hedge funds are snapping up shares 400,000 shares at a time! Major updates will be announced over the next few weeks sending this stock much higher then the current price per share. The stock closed very close to the daily high of $3.76 cents a share rising about 8% during Friday’s market session. Look for the stock to break $4.00 and then let the fun begin! Happy New Year’s to each and every one of you! We hope that 2012 is your biggest and best year yet! Endocyte, Inc.
3000 Kent Avenue
Suite A1-100
West Lafayette, IN 47906
United States - Map
Phone: 765-463-7175
Fax: 765-463-9271
Website: http://www.endocyte.com Endocyte, Inc., a biopharmaceutical company, engages in developing targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The company’s principal SMDC product, EC145, has been evaluated in a randomized phase 2 clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a phase 2 single-arm clinical trial for advanced non-small cell lung cancer. Its companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. Endocyte, Inc. was founded in 1995 and is based in West Lafayette, Indiana. http://hotpennystocksonline.com/?p=766
|
1 |
|
3 |
4 |
5 |
6 |
7
| 7
Thread abonnieren
